Bone seeking radiopharmaceuticals such as ethylenediaminetetramethylen
e phosphonate (EDTMP) complexes of samarium-153 and holmium-166 are re
ceiving considerable attention for therapeutic treatment of bone metas
tases. In this study, using the baboon experimental model, multicompar
tmental analysis revealed that with regard to pharmacokinetics, biodis
tribution, and skeletal localisation, Ho-166-EDTMP was significantly i
nferior to Sm-153-EDTMP and Tc-99m-MDP. A more suitable Ho-166-bone-se
eking agent should thus be sought for closer similarity to Sm-153-EDTM
P to exploit fully the therapeutic potential of its shorter half-life
and more energetic beta radiation. Copyright (C) 1996 Elsevier Science
Inc.